Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

First patient randomized in Phase 2 trial in head and neck cancer

Calliditas Therapeutics to participate in upcoming investor conferences

Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2018/2022

Calliditas provides a regulatory update on EMA process for Nefecon

Updated regulatory plans for NEFECON in China

Expansion of Everest Medicine’s licence agreement to include South Korea

First patient randomized in pivotal TRANSFORM study with setanaxib

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2022